{
    "organizations": [],
    "uuid": "beca85e0811ef7aeb742f3d578cf34d84f11eed4",
    "author": "",
    "url": "https://www.reuters.com/article/brief-european-commission-approves-amgen/brief-european-commission-approves-amgen-allergans-mvasi-idUSFWN1PD1CY",
    "ord_in_thread": 0,
    "title": "BRIEF-European Commission Approves Amgen, Allergan's Mvasi",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "January 18, 2018 / 9:08 PM / Updated 8 minutes ago BRIEF-European Commission Approves Amgen, Allergan's Mvasi Reuters Staff 1 Min Read \nJan 18 (Reuters) - Amgen Inc: \n* EUROPEAN COMMISSION APPROVES AMGEN AND ALLERGAN‘S MVASI® (BIOSIMILAR BEVACIZUMAB) FOR THE TREATMENT OF CERTAIN TYPES OF CANCER \n* AMGEN INC - EUROPEAN COMMISSION HAS GRANTED MARKETING AUTHORIZATION FOR MVASI Source text for Eikon: Further company coverage:",
    "published": "2018-01-18T23:07:00.000+02:00",
    "crawled": "2018-01-18T23:28:33.006+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "january",
        "pm",
        "updated",
        "minute",
        "ago",
        "commission",
        "approves",
        "amgen",
        "allergan",
        "mvasi",
        "reuters",
        "staff",
        "min",
        "read",
        "jan",
        "reuters",
        "amgen",
        "inc",
        "european",
        "commission",
        "approves",
        "amgen",
        "allergan",
        "biosimilar",
        "bevacizumab",
        "treatment",
        "certain",
        "type",
        "cancer",
        "amgen",
        "inc",
        "european",
        "commission",
        "granted",
        "marketing",
        "authorization",
        "mvasi",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}